Inhibition of lung tumorigenesis by NSAIDs: A working hypothesis

Experimental Lung Research

Volumn 24, Issue 4, 1998, Pages 605-615

  Castonguay, Andre ^a   Rioux, Nathalie ^a   Duperron, Caroline ^a   Jalbert, Guylaine ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Chemoprevention; Immune; Tobacco

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ANIMAL CELL; APOPTOSIS; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; IMMUNE RESPONSE; INFLAMMATORY CELL; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0031831512     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809087389     Document Type: Conference Paper

References (51)

1. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563-572.
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787-796.
3. IARC. Handbooks of Cancer Prevention, Vol 1: Non-steroidal Anti-Inflammatory Drugs. IARC publication. 1997:24-27.
4. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
5. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635-639.
6. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7:203-205.
7. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
8. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath, CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
9. Holtzman MJ. Arachidonic acid metabolism in airway epithelial cells. Annu Rev Physiol 1992;54:303-329.
10. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta. 1996;1299:125-140.
11. Arai I, Hamasaka Y, Futaki N, et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commum Chem Pathol Pharmacol. 1993;81:259-270.
12. Hussey HJ, Tisdale MJ. Inhibition of growth by lipoxygenase inhibitors. Br J Cancer. 1996;74:683-687.
13. Castonguay A, Pepin P, Stoner GD. Lung tumorigenicity of NNK given orally to A/J mice: its application to chemopreventive efficacy studies. Exp Lung Res. 1991;17:485-499.
14. Jalbert G, Castonguay A. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett. 1992;266:21-28.
15. Duperron C, Castonguay A. Chemoprevention efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18:1001-1006.
16. Hudson L, Hay FC. Practical Immunology, 3d ed. Oxford, UK: Blackwell Scientific; 1989:140-141.
17. Rioux N, Castonguay A. Recovery from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced immunosuppression in A/J mice by treatment with anti-inflammatory drugs. J Natl Cancer Inst. 1997;89:874-880.
18. Powell WS. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol. 1982;86:467-477.
19. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholinesterase. Methods Enzymol. 1990;87:24-34.
20. 4 using acetylcholinesterase. Methods Enzymol. 1990;187:82-89.
21. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor activity. J Immunol Methods. 1988;115:61-69.
22. Jorquera R, Castonguay A, Schuller HM. Effects of pregnancy and ethanol treatment on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by hamster liver and lung microsomes. Drug Metab Dispos. 1992;20:510-517.
23. Wattenberg LW. Inhibitors of chemical carcinogencsis. Adv Cancer Res. 1978;26:197-226.
24. Gorelik E, Herberman RB. Susceptibility of various strains of mice to urethan-induced lung tumors and depressed natural killer cell activity. J Natl Cancer Inst. 1981;67:1317-1322.
25. Boraschi D, Meltzer MS. Defective tumoricidal capacity of macrophages from A/J mice, III: genetic analysis of the macrophage defect. J Immunol. 1980;124:1050-1053.
26. Andersen P, Pedersen OF, Bach B, Bonde GJ. Serum antibodies and immunoglobulins in smokers and non-smokers. Clin Exp Immunol. 1982;47:467-473.
27. Holt PG. Immune and inflammation function in cigarette smokers. Thorax. 1987;42:241-249.
28. Grilli M, Chiu JJ, Lenarto MJ. NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1-62.
29. Spaziani EP, Lantz ME, Benoit RR, O'Brien WF. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4. Prostaglandins. 1996;51:215-223.
30. Coyne DW, Nickols M, Bertrand W, Morrison AR. Regulation of mesangial cell cyclooxytenase synthesis by cytokines and glucocorticoids. Am J Physiol. 1992;263:97-102.
31. Bauer MK, Lieb K, Schulze Osthoff K, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726-731.
32. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56:2556-2560.
33. Honn KV, Bockman RS, Marnett LJ. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins. 1981;21:833-864.
34. Brunda J, Herberman RB, Holde HT. Inhibition of murine natural killer cells by prostaglandins. J Immunol. 1980;124:2682-2687.
35. Droller MJ, Schneider MU, Perlman P. A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol. 1978;9:165-177.
36. Lala PK, Saarloos MN. Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: Harris JE, Braun DP, Anderson KM, eds. Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy. Boca Raton, FL: CRC Press; 1994:187-227.
37. Lee M, Kim HM, Yang KH. Down-regulation of protein kinase C in murine splenocytes: a potential mechanism for 2-acetylaminofluorene-mediated immunosuppression. Cancer Lett. 1996;19:53-57.
38. Smith TJ, Guo Zy, Thomas PE, et al. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes and its inhibition by isothiocyanates. Cancer Res. 1990;50:6817-6822.
39. Matzinger SA. Gunning WT, You M, Castonguay A. K-ras mutations in NNK-initiated and BHT-promoted lung tumors in A/J mice. Mol Carcinog. 1994;1:42-18.
40. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioassay. Adv Cancer Res. 1975;1:1-58.
41. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 1994;265:956-959.
42. Kazmi SM, Plante RK, Visconti V, Taylor GR, Zhou L, Lau CY. Suppression of NF-κB activation and NF-κB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Biochem. 1995;57:299-310.
43. Zhou L, Ritchie D, Wang EY, Barbone AG, Argentieri D, Lau CY. Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. J Immunol. 1994;153:5026-5037.
44. Piazza, GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57:2452-2459.
45. Pasricha PJ, Bedi A, O'Connor K, et al. The effect of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 1995;109:994-998.
46. Reddy BS, Rao CV, Rivenson A, Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993;14:1493-1497.
47. D716 knockout mice by inhibition of cyclooxygenase 2. Cell. 1996;87:803-809.
48. Natarajan K, Singh S, Burke TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc. Natl Acad Sci USA. 1996;93:9090-9095.
49. Rao CV, Desai D, Simi B, Kulkarni N, Amin S, Reddy BS. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and abberrant crypt foci formation in rat colon. Cancer Res. 1993;53:4182-4188.
50. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110-3116.
51. Duggan DE, Hare LE, Ditzler CA, Lei BW, Kwan KC. The disposition of sulindac in man. Clin Pharmacol Exp Ther. 1977;21:326-335.